Polpharma Biologics Integrates Bioceros
Company Plans To Retire The Bioceros Name Thereafter
Polpharma Biologics is making strategic moves to become a truly integrated CDMO by bringing its Dutch Bioceros subsidiary under the Polpharma Biologics brand.
You may also be interested in...
Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.
To boost the technology used in its digihaler family of inhalers, Teva has partnered with Amazon Web Services and Onica, a Rackspace Technology company. With this collaboration, Teva aims to protect patients’ information and ensure data security.